
FDA Approves Penpulimab-Kcqx for Indications in Nonkeratinizing Nasopharyngeal Carcinoma
The FDA approved penpulimab-kcqx (formerly AK105; Akeso Biopharma Co., Ltd.) for different indications within nonkeratinizing nasopharyngeal carcinoma (NPC). Penpulimab can be used with cisplatin (Platinol; Bristol Myers Squibb) or carboplatin (Paraplatin; …